Search

Aim. To identify factors and develop a clinical risk model (nomogram) for in-hospital mortality in patients with acute myocardial infarction (AMI) after timely early invasive diagnosis and revascularization of infarct-related artery (IRA).Material and methods: We conducted a prospective, single-center observational study that included 712 consecutive patients with AMI [median age 65 (interquartile range 56-74 years), 61% were male, 47.8% with ST-elevation] who underwent coronary angiography

Aim. To identify whether the addition of red blood cell distribution width (RDW) could improve the Global Registry of Acute Coronary Events (GRACE) risk score 2.0 in patients with acute myocardial infarction (AMI).Material and methods. This prospective observational study included 577 AMI patients who underwent coronary angiography within 24 hours after symptom onset. Admission RDW was measured as part of the automated complete blood count. GRACE 2.0 score at admission was calculated. The clinical endpoint was 18-month all-cause mortality. Logistic regression analysis was used to identify predictive values of RDW. Area under the receiver-operator characteristic (ROC) curve (AUC), net reclassification improvement (NRI) and integrated discrimination improvement (IDI) were calculated to evaluate the increment of predictive value for the combination of RDW with GRACE 2.0 score in predicting clinical adverse outcome.Results. The median age of patients was 65 (interquartile range: 56-74) years, while 60,7% were male. During 18-month follow-up, 66 patients (11,4%) died. RDW was positively correlated with GRACE 2.0 score (r=0,16, p

Aim. To outline echocardiographic features and assess their prognostic significance for major cardiovascular adverse events (MACEs) within 12 months in patients with type 2 myocardial infarction (MI), compared to type 1 MI (T1MI).Material and methods. The prospective observational study included 161 MI patients who underwent coronary angiography within 24 hours of admission. Type 2 MI (T2MI) diagnosis aligned with the Fourth Universal Definition. Echocardiography and speckle-tracking echocardiography were performed within 72 hours of hospitalization. MACEs encompassed cardiovascular death, non-fatal MI, non-fatal stroke, and HF-related readmissions. Logistic regression analysis was conducted to evaluate their associations with the outcomes.Results. T2MI were diagnosed in 74 patients (median age, 65 years; males, 55,4%). During follow up, 18 patients for each MI type experienced at least one MACE event. Left ventricular (LV) systolic dysfunction (LV ejection fraction [LVEF]

Serelaxin (recombinant molecule of the human relaxin-2) is an innovative drug for the treatment of acute heart failure. Preclinical and clinical studies demonstrated the ability of serelaxin to relieve the symptoms of heart failure, provide a significant reduction in congestion and have a protective effect on the heart, kidneys, liver. 48-hour serelaxin infusion in patient with ischemic cardiomyopathy and severe decompensated heart failure with cardio-hepatic syndrome led to significant regression of systemic congestion (evaluated by physical signs and by bioimpedance vector analysis), the improvement of structural and functional state of the myocardium (evaluated by standard echocardiography and global systolic longitudinal deformation of the left ventricle with speckle tracking echocardiography), regression of cardio-hepatic syndrome, improvement of renal function. Serelaxin therapy was well tolerated and was safe. Presented case report demonstrates beneficial effects of serelaxin on the heart failure symptoms and the organoprotective effects.